Early experience with simulect (basiliximab) induction in living donor renal allografting in India

By Siwach V.   Dhanda R.   Aggarwal B.   Singh B.   Jain P.K.   Sarin P.K.  

Transplantation Proceedings, Vol. 35, Iss. 1, 2003-02 ,pp. : 196-197

Elsevier

Access to resources Recommend Favorite

Duration of action of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in pediatric kidney transplant recipients

By Sterkers G.   Baudouin V.   Ansart-Pirenne H.   Maisin A.   Niaudet P.   Cochat P.   Loirat C.  

Transplantation Proceedings, Vol. 32, Iss. 8, 2000-12 ,pp. : 2757-2759

Elsevier

Access to resources Recommend Favorite

Blockade of intragraft IL-2 receptor- by basiliximab is insufficient to prevent activation of liver graft infiltrating cells

By Kwekkeboom J.   Warle M.C.   Rietveld J.   Segeren K.C.A.   Tilanus H.W.   Metselaar H.J.  

Transplant Immunology, Vol. 11, Iss. 1, 2003-01 ,pp. : 1-5

Elsevier

Access to resources Recommend Favorite

IL2-receptor antagonist (basiliximab) induction therapy is associated with lower morbidity and mortality in renal transplant recipients

By Choy B.Y.   Chan T.M.   Li F.K.   Lui S.L.   Lo W.K.   Yip T.   Tse K.C.   Lai K.N.  

Transplantation Proceedings, Vol. 35, Iss. 1, 2003-02 ,pp. : 195-195

Elsevier

Access to resources Recommend Favorite

Pharmacokinetics and pharmacodynamics of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in renal transplantation: a comparison between Japanese and non-Japanese patients

By Haba T.   Uchida K.   Katayama A.   Tominaga Y.   Sato T.   Watanabe I.   Inagaki H.   Kimata T.   Goto K.   Morozumi K.   Takeda A.   Takahara S.   Takahashi K.   Oshima S.  

Transplantation Proceedings, Vol. 33, Iss. 7, 2001-11 ,pp. : 3174-3175

Elsevier

Access to resources Recommend Favorite